Inhibiting a nuclear receptor in the gut could lead to a treatment for a liver disorder that affects almost 30 percent of the Western world's adult population, according to an international team of researchers.
The researchers found that tempol, an antioxidant drug, and antibiotics can treat and prevent nonalcoholic fatty liver disease in mice that were fed a high-fat diet. Nonalcoholic fatty liver disease -- NAFLD -- is a build up of fat in liver cells that disrupts liver function and, if left untreated, can lead to liver failure.